Unknown

Dataset Information

0

Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients.


ABSTRACT:

Background

Targeted therapy with tyrosine kinases inhibitors (TKIs) against epidermal growth factor receptor (EGFR) is part of routine clinical practice for EGFR mutant advanced non-small cell lung cancer (NSCLC) patients. These patients eventually develop resistance, frequently accompanied by a gatekeeper mutation, T790M. Osimertinib is a third-generation EGFR TKI displaying potency to the T790M resistance mutation. Here we aimed to analyze if exosomal RNAs, isolated from longitudinally sampled plasma of osimertinib-treated EGFR T790M NSCLC patients, could provide biomarkers of acquired resistance to osimertinib.

Methods

Plasma was collected at baseline and progression of disease from 20 patients treated with osimertinib in the multicenter phase II study TKI in Relapsed EGFR-mutated non-small cell lung cancer patients (TREM). Plasma was centrifuged at 16,000 g followed by exosomal RNA extraction using Qiagen exoRNeasy kit. RNA was subjected to transcriptomics analysis with Clariom D.

Results

Transcriptome profiling revealed differential expression [log2(fold-change) >0.25, false discovery rate (FDR) P<0.15, and P(interaction) >0.05] of 128 transcripts. We applied network enrichment analysis (NEA) at the pathway level in a large collection of functional gene sets. This overall enrichment analysis revealed alterations in pathways related to EGFR and PI3K as well as to syndecan and glypican pathways (NEA FDR <3×10-10). When applied to the 40 individual, sample-specific gene sets, the NEA detected 16 immune-related gene sets (FDR <0.25, P(interaction) >0.05 and NEA z-score exceeding 3 in at least one sample).

Conclusions

Our study demonstrates a potential usability of plasma-derived exosomal RNAs to characterize molecular phenotypes of emerging osimertinib resistance. Furthermore, it highlights the involvement of multiple RNA species in shaping the transcriptome landscape of osimertinib-refractory NSCLC patients.

SUBMITTER: Alexeyenko A 

PROVIDER: S-EPMC9641044 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients.

Alexeyenko Andrey A   Brustugun Odd Terje OT   Eide Inger Johanne Zwicky IJZ   Gencheva Radosveta R   Kosibaty Zeinab Z   Lai Yi Y   de Petris Luigi L   Tsakonas Georgios G   Grundberg Oscar O   Franzen Bo B   Viktorsson Kristina K   Lewensohn Rolf R   Hydbring Per P   Ekman Simon S  

Translational lung cancer research 20221001 10


<h4>Background</h4>Targeted therapy with tyrosine kinases inhibitors (TKIs) against epidermal growth factor receptor (EGFR) is part of routine clinical practice for EGFR mutant advanced non-small cell lung cancer (NSCLC) patients. These patients eventually develop resistance, frequently accompanied by a gatekeeper mutation, T790M. Osimertinib is a third-generation EGFR TKI displaying potency to the T790M resistance mutation. Here we aimed to analyze if exosomal RNAs, isolated from longitudinally  ...[more]

Similar Datasets

| S-EPMC6762027 | biostudies-literature
| S-EPMC5989837 | biostudies-literature
| S-EPMC8126145 | biostudies-literature
| S-EPMC10278531 | biostudies-literature
| S-EPMC4940973 | biostudies-literature
| S-EPMC10486675 | biostudies-literature
| S-EPMC10902357 | biostudies-literature
| S-EPMC9186160 | biostudies-literature
| S-EPMC10682450 | biostudies-literature
| S-EPMC7782093 | biostudies-literature